Sabarubicin (MEN-10755), a disaccharide analog of doxorubicin, is used for the treatment of small cell lung cancer (SCLC).[1] It has been seen to show superior antitumour efficacy, which is purported to be linked to the activation of p53-independent apoptosis[2]
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C32H37NO13 |
Molar mass | 643.642 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ Committee for Orphan Medicinal Products (6 October 2009). "Public summary of positive opinion for orphan designation of sabarubicin for the treatment of small cell lung cancer" (PDF). European Medicines Agency.
- ^ Arcamone FM (2008). "Sabarubicin". Topics in Current Chemistry. 283: 171–89. doi:10.1007/128_2007_1. PMID 23605632.